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Background: Differences in the susceptibility of Candida species to antifungal drugs make identification to the
species level important for clinical management of candidemia. Molecular tests are not yet standardized or available
in most clinical laboratories, although such tests can reduce the time required for species identification, as
compared to the conventional culture-based methods. To decrease laboratory costs and improve diagnostic
accuracy, different molecular methods have been proposed, including DNA extraction protocols to produce pure
DNA free of PCR inhibitors. The objective of this study was to validate a new format of molecular method, based
on the internal transcribed spacer (ITS) of the rDNA gene amplification followed by sequencing, to identify
common and cryptic Candida species causing candidemia by analyzing DNA in blood culture bottles positive
for yeasts.
Methods: For DNA extraction, an “in-house” protocol based on organic solvent extraction was tested. Additional
steps of liquid nitrogen incubation followed by mechanical disruption ensured complete cell lysis, and highly pure
DNA. One hundred sixty blood culture bottles positive for yeasts were processed. PCR assays amplified the ITS
region. The DNA fragments of 152 samples were sequenced and these sequences were identified using the
GenBank database (NCBI). Molecular yeast identification was compared to results attained by conventional method.
Results: The organic solvent extraction protocol showed high reproducibility in regards to DNA quantity, as well as
high PCR sensitivity (10 pg of C. albicans DNA and 95% amplification on PCR). The identification of species at the
molecular level showed 97% concordance with the conventional culturing method. The molecular method tested
in the present study also allowed identification of species not commonly implicated in human infections.
Conclusions: This study demonstrated that our molecular method presents significant advantages over the
conventional yeast culture identification method by providing accurate results within 24 hours, in contrast to at
least 72 hours required by the automated conventional culture method. Additionally, our molecular method
allowed the identification of mixed infections, as well as infections due to emergent fungal pathogens. This
economical DNA extraction method developed in our laboratory provided high-quality DNA and 60% cost savings
compared to commercial methods.
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Nosocomial candidemia remains a frequent cause of mor-
bidity and mortality, mainly among immunocompromised
and intensive care (ICU) patients [1-3]. Mortality remains
high, mainly due to the severity of underlying conditions
associated with candidemia, as well as limitations in the
conventional tools available for early diagnosis of this
infection [4-6].
The clinical signs of sepsis due to candidemia are
nonspecific, and diagnosis generally relies on conventional
blood culture, which is often delayed and presents sensi-
tivity lower than 70% [7,8]. Early diagnosis of this infection
is essential for proper antifungal therapy, and delays of
more than 12 hours in the administration of antifungal
agents may substantially increase mortality [9].
PCR methods for the diagnosis of Candida bloodstream
infections are not yet internationally standardized, and di-
vergent results may be obtained when different parame-
ters are used to perform the test. Indeed, there are still
controversies regarding the selection of biological material
to be tested (whole blood, plasma or serum), various pro-
tocols for DNA extraction, the gene target to be analyzed,
the PCR assay used (conventional, nested, PCR-RFLP or
real time), the number of cycles, the detection limit and
the parameters used for sequences analysis [10-16]. In the
absence of commercial systems largely validated in multi-
center studies, “in-house” PCR based methods remain
used worldwide for the diagnosis of candidemia.
In the present study, we validated a new format of
molecular method based on ITS-PCR followed by se-
quencing to identify common and cryptic Candida spe-
cies causing candidemia by analyzing fungal DNA in
yeast-positive blood culture bottles using a rapid and ac-
curate molecular method. We also standardized a low-
cost method for DNA extraction, developed “in-house”,
that yielded highly purified DNA and provided 60% cost
savings compared to the commercial methods.
Results and discussion
Fungal DNA extraction
DNA was purified from blood samples using an extrac-
tion method described below that yielded high-quality
DNA (high purity with respect to proteins and salt, optical
density (OD) 260/280 and 260/230 with rate values ≥ 1.8)
and decreased the effect of PCR inhibitors such as hemo-
globin and some components of the culture medium.
It has been well documented that the fungal cell wall
is an important obstacle to nucleic acid extraction and
that the effectiveness of the cell lysis and DNA extraction
highly influences the sensitivity of PCR assays [17,18].
Our methodology included two important cell lysis
steps: freezing the sample with liquid nitrogen and agita-
tion with glass beads. Both procedures have been suc-
cessfully used by other authors to attain fungal cell lysisand DNA extraction [18-20]. We used the Brazol® reagent
(guanidine thiocyanate), an inexpensive compound that is
able to disrupt cell membranes, fragment chromosomes,
and prevent DNA from being trapped in clinical sample
residues, reducing the activity of PCR inhibitors [21].
Our extraction protocol was designed to extract both
intracellular and extracellular DNA from the sample
[22]. This protocol was standardized by testing negative
blood culture bottles and C. albicans-spiked blood cul-
ture as negative and positive controls, respectively (data
not shown).
This “in-house”-developed DNA extraction method
provided approximately 60% cost savings compared to
commercial methods.
PCR for fungal ITS amplification and sequencing
Of 160 DNA samples extracted from blood culture bot-
tles positive for yeasts, successful amplification of the
ITS was achieved in 152 samples (95%) using our PCR
methodology. Our method yielded fragments of 400-700
bp (see Figure 1A).
The ITS 1, ITS 2 and 5.8S regions of rDNA have
already been well documented as a reliable target for
amplification and sequencing, useful for discriminating
between medically important yeasts [10,23]. Within the
ITS rDNA region, we selected the universal fungal-
specific primers ITS1 and ITS4 because our preliminary
studies demonstrated that these primers were more spe-
cific for fungal DNA, presenting lower levels of cross-
reaction with human DNA than other primers. We also
used a high hybridization temperature (58°C), which
allowed the specific amplification of fungal DNA. The
ITS sequences were obtained using the same primers
used in the PCR assay. Results from BLASTn that pro-
vided an e-value less than 10-5 and a maximum identity
higher than 98% were considered reliable for identifica-
tion of Candida species.
Only 8 infection samples could not be amplified by our
PCR method, as follows: 2 samples of C. albicans, 2 sam-
ples of C. parapsilosis, 2 samples of C. tropicalis, 1 sample
of C. pelliculosa (Pichia anomala) and 1 mixed infection
sample of C. parapsilosis and C. guilliermondii. To check
for the presence of PCR inhibitors, C. albicans ATCC
24433 genomic DNA was added to each sample prior to
the PCR assay. These samples could not be amplified des-
pite the addition of C. albicans DNA (Figure 1B). These
findings suggest that the cause of negative PCR results
was neither the detection limit of yeast DNA for the test
nor insufficient DNA quantities in the sample. Rather, it
was caused by the presence of PCR inhibitors that were
not removed by Brazol during DNA extraction or by the
addition of bovine serum albumin (BSA) to the PCR assay.
The presence of PCR inhibitors such as hemoglobin,
lactoferrin and sodium polyanetholesulfonate from
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Figure 1 Amplification of DNA extracted from positive blood culture bottles for yeasts. One percent agarose gels presenting the PCR
product from: A) Six positive samples amplified through our molecular method, yielding fragments of 400-700 bp; B) Four positive samples
representative of eight samples that could not be amplified by our method. These samples were spiked with DNA extracted from C. albicans
ATCC 24433. None of the samples could be amplified, in spite of the addition of C. albicans DNA. * Samples spiked with C. albicans ATCC 24433
DNA; (C-) Negative control (PCR grade water); (C+) Positive control (C. albicans ATCC 24433 DNA).
Table 1 Comparison of phenotypic and genotypic
identification of yeasts obtained from positive blood
culture bottles
Phenotypic identification Genotypic identification
Species Number of
identified
samples
Species Number of
identified
samples
C. albicans 41 C. albicans 40
C. albicans + C. glabrata 1
C. glabrata 28 C. glabrata 28
C. guilliermondii 4 Meyerozyma
guilliermondii
2
Clavispora lusitaniae 1
C. intermedia 1
C. krusei 15 Issatchenkia orientalis 15
C. lusitaniae 1 Clavispora lusitaniae 1
C. norvegensis 1 Pichia norvegensis 1
C. parapsilosis
(sensu lato)
34 C. parapsilosis (sensu
stricto)
27
C. orthopsilosis 7
C. pelliculosa 1 C. haemulonii 1
C. tropicalis 26 C. tropicalis 26
C. glabrata + C.
albicans
1 C. albicans 1
Total 152 152
Issatchenkia orientalis: teleomorph of C. krusei; Clavispora lusitaniae:
teleomorph of C. lusitaniae; Meyerozyma guilliermondii: teleomorph of C.
guilliermondii; Pichia norvegensis: teleomorph of C. norvegensis.
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spectively, may explain false negative results generated
along DNA amplification from clinical samples [24].
The inhibitory effect of hemoglobin and lactoferrin
seems to be related to the ability of these proteins to re-
lease iron ions. The inhibitory effect of iron ions appears
to act directly on the DNA polymerase by competing
with the template. Lactoferrin also appears to interact
with nucleic acids. Al-Soud and Radstrom [24] tested
several amplification facilitators in the presence of
hemoglobin and lactoferrin. BSA was the most efficient
compound in reducing inhibition of amplification, due
to its binding efficiency. Consequently, BSA is often
used to increase the sensitivity of PCR amplification
from clinical samples [24-26].
With the exception of the 8 samples that were not
amplified in this study, the addition of BSA to the PCR
assay allowed us to amplify most of the samples.
Comparison between the conventional culture-based
Candida spp. identification method and our molecular
method
The identification of Candida spp. obtained by the con-
ventional culture-based and molecular methods is shown
on Table 1. The results of the genotypic identification
method correlated highly with the conventional culture-
based identification method (97%). It is important to stress
that discordant identifications corresponded to cryptic
species (e.g., the C. haemulonii, C. intermedia and C.
parapsilosis species complex). These species were not ac-
curately identified by the conventional method but were
identified by the present PCR- and sequencing-based
method. In addition, our molecular method was able to
identify one episode of mixed infection (C. albicans and
C. glabrata), while the conventional culture-based method
recognized only C. albicans in the mixed infection. This
difference between assays is most likely due to the un-
viability of C. glabrata cells for culture, rendering them
undetectable by the conventional culture-based method.However, the persistence of detectable DNA in the sample
allowed for successful identification by the molecular
method. In contrast, one episode of mixed infection
caused by C. glabrata and C. albicans was recognized by
the culture method, while our molecular method identi-
fied only C. albicans. This anomaly was most likely the re-
sult of low burden of C. glabrata in the sample, especially
in the low volume of extracted DNA used for PCR assay.
As noted by Pfeiffer et al. [22], despite the high sensitivity
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rally required to detect fungal DNA.
In contrast with methodologies that adopt real-time
PCR and/or nested PCR [27,28], our method is not
limited to the use of a small number of probes or
primers. Our method also provides accurate identifica-
tion of emergent pathogens and novel sequence variants
for which species-specific primers or probes have not
yet been validated.
Through this molecular method, after the bottles with
positive cultures were detected, we were able to extract
DNA from the blood cultures and accurately identify
fungal species within 24 hours, while the conventional
non-automated method would take at least 72-96 hours
[29]. Morrell et al. [6] has previously demonstrated that
a 12-hour delay in the initiation of antifungal treatment
is sufficient time to double mortality in patients with
candidemia. By using the ITS-PCR and sequencing
method developed in this study, it is possible to reduce
the time required to identify the causal yeast species in
an infection by 48 hours compared to the conventional
culture-based method.
Performance of ITS-PCR and sequencing compared to
other molecular methods
The ITS-PCR and sequencing method validated in our
laboratory showed low-cost, reliable and accurate Can-
dida species identification; it yielded accurate final iden-
tification in 152 out of 160 (95%) blood cultures tested.
The reproducibility of the assay was 100% as checked by
a pilot study testing negative blood culture bottles spiked
with cultured Candida spp. cells (data not shown). Our
molecular method allowed the identification of rare and
cryptic species, such as C. intermedia, C. haemulonii
and C. orthopsilosis (the last one is a species of the C.
parapsilosis complex). Identification was accomplished
with tools and techniques that are accessible to routine
laboratories, including a low-cost “in-house” DNA ex-
traction protocol and an automatic sequencer that uses
the Sanger method.
A large variety of PCR-based methods has been ap-
plied to identify candidemia in blood culture bottles, but
most of these methods used specific primers and probes
that may potentially limit the number of species that can
be identified. Shin et al. has described a clinically useful
PCR method, followed by identification with species-
specific probes that could detect only the five most com-
mon Candida species in 73 blood culture bottles from
31 candidemic patients [29]. These probes could not
identify cryptic species of the C. parapsilosis complex,
C. orthopsilosis and C. metapsilosis.
Other authors have developed semi-nested or multi-
plex PCR methods involving the amplification of yeast
rDNA regions, resulting in fragments of different sizesfor species identification. These methods were not able
to differentiate between all the species tested, including
the rare and cryptic species, especially the ones classi-
fied in species complex, such as C. parapsilosis and
C. guilliermondii [10,30-32].
Other PCR-based methods followed by DNA sequen-
cing have been successfully developed. However, these
studies have used commercial methods for DNA extrac-
tion, which makes this process more expensive than our
“in-house”-developed DNA extraction method [33,34].
Additionally, Quiles-Melero et al. used a PCR-based
methodology coupled with pyrosequencing [34]. The au-
thors reported accurate Candida spp. identification in all
47 blood culture bottles tested, yielding 100% correlation
with the conventional method. However, pyrosequencing
methodology is not available for candidemia diagnosis
in most medical centers.
Conclusions
Several studies have been published describing the use
of conventional, nested or real-time PCR in positive
blood culture bottles to identify yeast species; however,
no molecular methodology has been broadly adopted for
the identification of yeast species in modern clinical la-
boratories. Even direct PCR of blood from patients with
suspected candidemia would provide more rapid species
identification. Unfortunately, this methodology yields
low positivity due to the low fungal burdens usually
present in whole blood samples [15,22,35,36].
In the present study, we described and validated a new
format for a molecular-based method of yeast identifica-
tion. This method is based on ITS-PCR followed by se-
quencing to identify common, rare and cryptic Candida
species that cause candidemia and are present in yeast-
positive blood culture bottles. This molecular method
for the identification of Candida spp. had a significant
advantage over the conventional culture-based identifi-
cation method by providing accurate results within
24 hours, in contrast to at least 72 hours required by the
automated conventional culture. The molecular method
developed in this study additionally provided identifica-
tion of mixed infections as well as infections due to
emergent fungal pathogens. Furthermore, the low-cost
DNA extraction method developed in our laboratory
provided high-quality DNA and 60% cost-savings com-
pared to commercial methods.
Methods
Selection of biological samples and controls for PCR
We selected a total of 160 yeast-positive blood culture
bottles among 405 bottles of the BACTEC system yield-
ing yeasts that were sequentially processed in the clinical
laboratory of the Hospital São Paulo, Universidade
Federal de São Paulo, between October 2008 and
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growth in blood cultures, aliquots from each bottle
were taken for conventional fungal culture and micro-
organism identification. Finally, aliquots of 3-4 mL of each
bottle processed during the period were stored at -20°C
for further PCR analysis.
The selection of samples for further PCR assays aimed
to include cultures representative of most clinically rele-
vant species of Candida based on the initial phenotypic
identification obtained in our clinical laboratory of the
yeasts growing in blood cultures. Based on the initial
identification of yeast colonies generated by the ID 32
system and complemented by the micromorphology fin-
dings, 152 cultures were studied. These cultures included
the most common species that cause candidemia: C.
albicans (41/27.1%), C. parapsilosis (34/22.5%), C. tropicalis
(26/17.2%), C. glabrata (28/18.5%), C. krusei (15/9.9%), and
C. guilliermondii (4/2.6%). In addition, we selected 3 cases
representative of candidemic episodes due to unusual pa-
thogens as identified by the ID-32 system: C. pelliculosa
(1/0.7%), C. lusitaniae (1/0.7%) and C. norvegensis (1/0.7%).
We also included one case of mixed infection caused by C.
albicans and C. glabrata (1/0.7%).
Finally, as negative controls for the Candida PCR
assay, we included DNA samples from blood cultures
representative of sepsis due to Gram-positive (10 sam-
ples) and Gram-negative bacteria (10 samples), as well
as 10 negative blood cultures. Genomic DNA extracted
from the reference strain Candida albicans ATCC
24433 was used as a positive control.
DNA extraction from blood culture bottles
DNA was extracted from all samples according to the
method adapted from Sandhu et al. [21]. For this pro-
cedure, 300 μL of each sample and 200 μL of glass beads
were added to a 1.5 mL microtube, incubated in liquid
nitrogen for 2 minutes and vigorously shaken for 3 cy-
cles of 45 seconds in a FastPrep homogenizer at speed
5.0. After cooling the tubes on ice, 600 μL of room
temperature Brazol was added and the tubes were
vortexed. Subsequently, 130 μL of cold chloroform was
added, and the tubes were shaken again. The samples
were then centrifuged at 20,000 × g, at 8°C for 12 mi-
nutes and the supernatants were transferred to new
tubes containing 500 μL of cold absolute ethanol. The
tubes were shaken by hand, and the samples were again
centrifuged at 20,000 × g at 8°C for 12 minutes. The pel-
lets were washed twice with 500 μL of 70% ethanol,
dried and resuspended in 30 μL of Milli-Q water. Each
sample was tested for DNA quantity, and protein and
salt contamination via reading at OD 260/280 and 260/
230, respectively. DNA was re-extracted from samples
that had ratios <1.8. Purified DNA was stored at -20°C
until further procedures were performed.PCR assay for rDNA ITS region amplification
To amplify the rDNA ITS1, 5.8 S, and ITS2 regions, we
performed PCR assays with the primer pair ITS1 and
ITS4 at 10 pmol/μL, in a final volume of 25 μL
containing: 12.5 μL of PCR MasterMix (Promega, Madi-
son, WI – USA), 2 μL ITS1 primer (forward), 2 μL of
ITS4 primer (reverse), 2.5 μL of 5% BSA, 4 μL of Milli-
Q water and 2 μL of DNA sample. The thermal cycling
protocol used was as follows: an initial denaturation
phase of 5 minutes at 94°C, followed by 35 cycles of
94°C for 1 minute, 58°C for 1 minute, 72°C for 2 mi-
nutes, and finally an additional extension phase at 72°C
for 10 minutes. Each PCR batch included one reaction
containing Milli-Q water as a negative control and one
reaction containing DNA extracted from C. albicans
ATCC 24433 culture as a positive control.
The PCR samples were submitted to agarose gel elec-
trophoresis to verify DNA amplification. When two or
more amplicons were visualized on a gel, each band was
purified using a GFX kit (GE Healthcare, UK), and each
fragment was sequenced independently.ITS sequencing and yeast species identification
The sequencing reaction was performed through the
addition of 2 μL of diluted amplicon (1:10 to intense
bands, 1:5 to weak bands) to a reaction mix containing
2 μL of BigDye Terminator (Applied Biosystems, USA),
4 μL of sequencing buffer (Applied Biosystems, USA),
4 μL of Milli-Q water and 3 μL of 2 pmol/μL primer, in
a total reaction volume of 15 μL. The reactions were
submitted to 25 thermal cycles as follows: 95°C for
20 seconds, 50°C for 15 seconds and 60°C for 1 minute.
The reactions were precipitated through the addition of
2 μL of 3 M sodium acetate/well, 2 μL of 125 mM
EDTA/well and 55 μL of ethanol per well and then de-
natured through the addition of 15 μL of formamide
HiDi (Applied Biosystems, USA) and incubation at 94°C
for 4 minutes. Finally, the samples were rapidly cooled
on ice before the reactions were run on the automatic
sequencer.
The amplicons were sequenced using the Sanger
methodology in a MicroAmp – Optical 96-well reaction
plate (Applied Biosystems, USA) and the automatic se-
quencer ABI 3130 (Applied Biosystems, USA). At least 2
reads were generated for each sample.
The chromatograms generated by each sample were
assembled into contigs and edited using the software
programs Phred Phrap and Consed, respectively [37-40].
Alignments with <100 errors per 10 Kb were considered
valid. The sequences were then compared to the NCBI
genomic database using the BLASTn tool. Species iden-
tifications were accepted when the BLASTn values were
e-value < 10-5 and identity ≥ 98% [41].
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Species identification generated by our PCR method was
compared to results obtained by the conventional culture-
based identification method.
Putative assays with no PCR amplification were
checked for the presence of PCR inhibitors through the
addition of C. albicans ATCC genomic DNA.
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